Novo Nordisk Stock Surges 5.13% on Phase 3 Trial Launch for Weight Loss Drug CagriSema Ranking 69th in Trading Volume

On June 10, 2025, Novo Nordisk (NVO) saw a trading volume of 10.35 billion, ranking 69th in the day's stock market activity. The company's stock price surged by 5.13%, marking its fifth consecutive day of gains and a total increase of 11.87% over the past five days.

Novo Nordisk has initiated a new Phase 3 trial for its next-generation weight loss drug, CagriSema. This trial aims to assess the drug's effectiveness in helping individuals with obesity achieve and maintain long-term weight loss. The company's decision to launch this trial comes after previous data showed disappointing results, indicating a need for further research and development.

At the ADA 2025 conference, Novo Nordisk presented strong data from its portfolio, including new results for semaglutide and CagriSema. These findings highlight the company's advancements in obesity and diabetes care, positioning it as a leader in the field. The positive data from these trials has contributed to the optimism surrounding Novo Nordisk's stock performance.